サマリー

市場分析と洞察。T細胞・NK細胞エンゲージド・バスペシフィック抗体の世界市場
当レポートは、世界および日本のT-Cell & NK-Cell Engaging Bispecific Antibodies市場に焦点を当てています。
2021年の世界のT-Cell & NK-Cell Engaging Bispecific Antibodiesの市場規模は4億7200万米ドルで、2021年から2028年の間に40.82%のCAGRで、2028年末には5億7200万米ドルに達すると予測されます。日本では、T細胞・NK細胞エンゲージド・バイスペシフィック抗体の市場規模は2021年の188万米ドルから2028年には1億7315万米ドルに成長し、予測期間中に99.82%のCAGRで成長すると予測されます。

世界のT細胞・NK細胞エンゲージド・バスペシフィック抗体の範囲と市場規模
T細胞およびNK細胞関与型ビスペシフィック抗体の市場は、プレイヤー、地域（国）、タイプ、および用途別に区分されています。世界のT-Cell & NK-Cell Engaging Bispecific Antibodies市場におけるプレイヤー、ステークホルダー、その他の参加者は、このレポートを強力なリソースとして利用することで、優位に立つことができます。セグメント別分析では、2017-2028年の期間において、Type別とBy Application別の収益と予測に焦点を当てます。

企業別
アムジェン
イムノコア
ジョンソン・エンド・ジョンソン
ロシュ
5社
アッヴィ
マクロジェニックス
リジェネロン
アステラス製薬
GEMoaB モノクローナルズ
モレキュラー・パートナーズ
アストラゼネカ
メルク
イーライリリー
IGMバイオサイエンシズ
ノバルティス
サイトムXセラピューティック
ラバ・セラピューティック
武田薬品工業

タイプ別セグメント
T細胞エンゲージャー
NK細胞エンゲージャー

アプリケーション別セグメント
血液がん
固形がん

地域別
北米
米国
カナダ
メキシコ

アジア・パシフィック
中国
日本
韓国
東南アジア
オーストラリア
インド
その他のアジア

欧州
ドイツ
フランス
英国
イタリア
ロシア
その他の欧州

南米
ブラジル
南米のその他

中近東・アフリカ
中東
アフリカ

ページTOPに戻る

目次

1 REPORT OVERVIEW 1
1.1 Study Scope 1
1.2 Market Analysis by Type 2
1.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 2
1.2.2 T Cell Engagers 3
1.2.3 NK Cell Engagers 4
1.3 Market by Application 5
1.3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Application: 2017 VS 2021 VS 2028 5
1.3.2 Hematological Cancers 7
1.3.3 Solid Tumors 7
1.4 Study Objectives 7
1.5 Years Considered 8
2 GLOBAL GROWTH TRENDS 9
2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Perspective (2017-2028) 9
2.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Growth Trends by Regions 10
2.2.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Regions: 2017 VS 2021 VS 2028 10
2.2.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Size by Regions (2017-2022) 12
2.2.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Regions (2023-2028) 12
2.2.4 Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share in Global Market 2017-2028 14
2.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Dynamic 14
2.3.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Trends 14
2.3.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Drivers 15
2.3.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Challenges 16
2.3.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Restraints 16
3 COMPETITION LANDSCAPE BY KEY PLAYERS 17
3.1 Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Players by Revenue 17
3.1.1 Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Players by Revenue (2017-2022) 17
3.1.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Players (2017-2022) 17
3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) 18
3.3 Players Covered: Ranking by T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue 19
3.4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Concentration Ratio 19
3.4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Concentration Ratio (CR5 and HHI) 19
3.4.2 Global Top 2 Companies by T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue in 2021 20
3.5 T-Cell & NK-Cell Engaging Bispecific Antibodies Key Players Head office and Area Served 20
3.6 Key Players T-Cell & NK-Cell Engaging Bispecific Antibodies Product Solution and Service 21
3.7 Date of Enter into T-Cell & NK-Cell Engaging Bispecific Antibodies Market 21
3.8 Mergers & Acquisitions, Expansion Plans 22
4 T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES BREAKDOWN DATA BY TYPE 24
4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Size by Type (2017-2022) 24
4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Type (2023-2028) 25
5 T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES BREAKDOWN DATA BY APPLICATION 26
5.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Size by Application (2017-2022) 26
5.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Application (2023-2028) 27
6 NORTH AMERICA 28
6.1 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028) 28
6.2 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) 28
6.3 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) 29
6.4 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022) 29
6.4.1 United States 30
6.4.2 Canada 31
6.4.3 Mexico 32
7 EUROPE 33
7.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028) 33
7.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) 33
7.3 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) 34
7.4 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022) 34
7.4.1 Germany 36
7.4.2 France 37
7.4.3 U.K. 38
7.4.4 Italy 39
7.4.5 Russia 40
8 ASIA-PACIFIC 41
8.1 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028) 41
8.2 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) 41
8.3 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) 42
8.4 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Region (2017-2022) 42
8.4.1 China 43
8.4.2 Japan 44
8.4.3 South Korea 45
8.4.4 Southeast Asia 45
8.4.5 India 46
9 SOUTH AMERICA 47
9.1 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028) 47
9.2 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) 47
9.3 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) 48
9.4 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022) 48
9.4.1 Brazil 49
10 MIDDLE EAST & AFRICA 50
10.1 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028) 50
10.2 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) 50
10.3 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) 51
10.4 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022) 51
10.4.1 Middle East 52
10.4.2 Africa 53
11 KEY PLAYERS PROFILES 54
11.1 Amgen 54
11.1.1 Amgen Company Details 54
11.1.2 Amgen Business Overview 54
11.1.3 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 55
11.1.4 Amgen Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies Business (2017-2022) 56
11.1.5 Amgen Recent Development 56
11.2 Immunocore 57
11.2.1 Immunocore Company Details 57
11.2.2 Immunocore Business Overview 58
11.2.3 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 58
11.2.4 Immunocore Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies Business (2017-2022) 59
11.2.5 Immunocore Recent Development 59
11.3 Johnson & Johnson 60
11.3.1 Johnson & Johnson Company Details 60
11.3.2 Johnson & Johnson Business Overview 60
11.3.3 Johnson & Johnson T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 61
11.3.4 Johnson & Johnson Recent Development 62
11.4 Roche 62
11.4.1 Roche Company Details 62
11.4.2 Roche Business Overview 63
11.4.3 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 63
11.4.4 Roche Recent Development 64
11.5 Pfizer 65
11.5.1 Pfizer Company Details 65
11.5.2 Pfizer Business Overview 65
11.5.3 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 66
11.5.4 Pfizer Recent Development 66
11.6 AbbVie 66
11.6.1 AbbVie Company Details 66
11.6.2 AbbVie Business Overview 67
11.6.3 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 67
11.6.4 AbbVie Recent Development 68
11.7 MacroGenics 68
11.7.1 MacroGenics Company Details 68
11.7.2 MacroGenics Business Overview 69
11.7.3 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 69
11.7.4 MacroGenics Recent Development 69
11.8 Regeneron 70
11.8.1 Regeneron Company Details 70
11.8.2 Regeneron Business Overview 70
11.8.3 Regeneron T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction 70
11.8.4 Regeneron Recent Development 71
11.9 Astellas Pharma 71
11.9.1 Astellas Pharma Company Details 71
11.9.2 Astellas Pharma Business Overview 71
11.9.3 Astellas Pharma Recent Development 72
11.10 GEMoaB Monoclonals 72
11.10.1 GEMoaB Monoclonals Company Details 72
11.10.2 GEMoaB Monoclonals Business Overview 73
11.10.3 GEMoaB Monoclonals Recent Development 73
11.11 Molecular Partners 74
11.11.1 Molecular Partners Company Details 74
11.11.2 Molecular Partners Business Overview 74
11.11.3 Molecular Partners Recent Development 74
11.12 AstraZeneca 75
11.12.1 AstraZeneca Company Details 75
11.12.2 AstraZeneca Business Overview 75
11.12.3 AstraZeneca Recent Development 76
11.13 Merck 76
11.13.1 Merck Company Details 76
11.13.2 Merck Business Overview 76
11.13.3 Merck Recent Development 77
11.14 Eli Lilly 77
11.14.1 Eli Lilly Company Details 77
11.14.2 Eli Lilly Business Overview 78
11.14.3 Eli Lilly Recent Development 78
11.15 IGM Biosciences 79
11.15.1 IGM Biosciences Company Details 79
11.15.2 IGM Biosciences Business Overview 79
11.15.3 IGM Biosciences Recent Development 80
11.16 Novartis 80
11.16.1 Novartis Company Details 80
11.16.2 Novartis Business Overview 80
11.16.3 Novartis Recent Development 81
11.17 CytomX Therapeutics 81
11.17.1 CytomX Therapeutics Company Details 81
11.17.2 CytomX Therapeutics Business Overview 82
11.17.3 CytomX Therapeutics Recent Development 82
11.18 Lava Therapeutics 83
11.18.1 Lava Therapeutics Company Details 83
11.18.2 Lava Therapeutics Business Overview 83
11.18.3 Lava Therapeutics Recent Development 83
11.19 Takeda 84
11.19.1 Takeda Company Details 84
11.19.2 Takeda Business Overview 84
11.19.3 Takeda Recent Development 84
12 ANALYST'S VIEWPOINTS/CONCLUSIONS 86
13 APPENDIX 88
13.1 Research Methodology 88
13.1.1 Methodology/Research Approach 88
13.1.2 Data Source 91
13.2 Disclaimer 94
13.3 Author Details 95